Discontinued — last reported Q1 '26
Welireg — Sales
Merck & Co. Welireg — Sales decreased by 54.9% to $199.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 27.6%, from $275.00M to $199.00M. Over 4 years (FY 2021 to FY 2025), Welireg — Sales shows an upward trend with a 172.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration, expanded clinical indications, or growing physician adoption, while a decrease may signal increased competition, patent challenges, or declining demand.
Detailed definition
This metric represents the total annual revenue generated from the sale of Welireg, a therapeutic product within the com...
Peer comparison
Comparable to revenue metrics for specific high-growth oncology or specialty pharmaceutical products at peer biopharmaceutical companies.
mrk_segment_welireg_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.50M | $6.50M | $6.50M | $36.00M | $54.00M | $76.00M | $80.00M | $84.00M | $101.00M | $108.00M | $144.00M | $169.00M | $252.00M | $278.00M | $319.00M | $275.00M | $324.00M | $392.00M | $441.00M | $199.00M |
| QoQ Change | — | +0.0% | +0.0% | +453.8% | +50.0% | +40.7% | +5.3% | +5.0% | +20.2% | +6.9% | +33.3% | +17.4% | +49.1% | +10.3% | +14.7% | -13.8% | +17.8% | +21.0% | +12.5% | -54.9% |
| YoY Change | — | — | — | — | +730.8% | >999% | >999% | +133.3% | +87.0% | +42.1% | +80.0% | +101.2% | +149.5% | +157.4% | +121.5% | +62.7% | +28.6% | +41.0% | +38.2% | -27.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s welireg — sales?
- Merck & Co. (MRK) reported welireg — sales of $199.00M in Q1 2026.
- How has Merck & Co.'s welireg — sales changed year-over-year?
- Merck & Co.'s welireg — sales decreased by 27.6% year-over-year, from $275.00M to $199.00M.
- What is the long-term trend for Merck & Co.'s welireg — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s welireg — sales has grown at a 172.4% compound annual growth rate (CAGR), from $26.00M to $1.43B.
- What does welireg — sales mean?
- The total annual revenue generated from the sale of the Welireg pharmaceutical product.